Febuxostat

Gout Management

Febuxostat is used for the long-term management of hyperuricemia (high uric acid levels) in adults with gout. Gout is a form of arthritis that occurs when uric acid builds up in the body and forms crystals in the joints, leading to sudden episodes of pain, swelling, and redness.

When It Is Prescribed

Because of specific safety considerations, healthcare providers typically reserve febuxostat for patients who cannot be treated effectively with other medications. It is generally prescribed for people who:

• Have tried allopurinol and found it did not lower their uric acid levels enough.
• Experienced severe or intolerable side effects from allopurinol.
• Have medical reasons why allopurinol treatment is not recommended.

Limitations of Use

Febuxostat is intended to prevent future gout attacks by maintaining low uric acid levels over time. It is not used to treat the symptoms of a gout flare that is already occurring. Additionally, it is not recommended for people who have high uric acid levels but have never experienced symptoms of gout.

Mechanism of Action

Febuxostat belongs to a class of medications known as xanthine oxidase inhibitors. It works by interfering with the process the body uses to create uric acid.

Reducing Uric Acid Production

The body produces uric acid when it breaks down purines, which are substances found naturally in the body and in certain foods. An enzyme called xanthine oxidase is responsible for the final steps of converting these purines into uric acid. Febuxostat binds to this enzyme and blocks its activity, which results in a significant decrease in the amount of uric acid released into the bloodstream.

Preventing Gout Flares

Gout is a type of arthritis caused by the buildup of needle-like uric acid crystals in the joints and surrounding tissues. These crystals form when there is too much uric acid in the blood (hyperuricemia). By keeping uric acid levels low, febuxostat helps to:

• Stop new crystals from forming in the joints.
• Allow existing crystals to slowly dissolve over time.
• Decrease the frequency of painful gout attacks.

It is important to understand that febuxostat is a long-term maintenance medication. It does not provide immediate pain relief and is not used to treat a gout attack that is already in progress.

Common Side Effects

Some people may experience mild side effects while taking febuxostat. These often do not require urgent medical care but should be discussed with a healthcare provider if they persist or become bothersome:

• Nausea
• Joint pain or stiffness
• Mild skin rash
• Dizziness

When you first start taking febuxostat, you may experience an increase in gout flares. Your doctor may prescribe other medications to help prevent these flares during the first few months of treatment.

Serious Side Effects

Seek medical help immediately if you experience any of the following serious symptoms:

• Heart-related symptoms: Chest pain, shortness of breath, rapid or irregular heartbeat, or sudden dizziness.
• Stroke symptoms: Sudden numbness or weakness (especially on one side of the body), slurred speech, or vision changes.
• Liver problems: Extreme tiredness, loss of appetite, pain in the upper right side of the stomach, dark urine, or yellowing of the skin or eyes.
• Severe skin reactions: Red or purple skin rash, blistering or peeling skin, or sores in the mouth or around the eyes.
• Allergic reactions: Hives, swelling of the face, lips, tongue, or throat, and difficulty breathing.

Boxed Warning: Risk of Death

Clinical trials have shown that febuxostat is associated with a higher risk of heart-related death and death from all causes compared to allopurinol. Because of this risk, healthcare providers generally reserve febuxostat for patients who have not responded well to allopurinol, cannot tolerate it, or for whom allopurinol is not recommended.

Cardiovascular Risks

Patients taking febuxostat should be monitored for signs of serious cardiovascular events, including heart attack and stroke. Immediate medical attention is necessary if symptoms such as chest pain, shortness of breath, sudden numbness or weakness, or difficulty speaking occur.

Liver Function

Febuxostat can cause elevations in liver enzymes, which may indicate liver injury. Healthcare providers typically perform blood tests to check liver function before starting the medication and may repeat these tests periodically during treatment. Symptoms of liver problems include fatigue, jaundice (yellowing of the skin or eyes), and dark urine.

Serious Skin Reactions

Rare but serious skin reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, have been reported. Treatment should be stopped immediately if a skin rash or other signs of a hypersensitivity reaction develop.

Drug Interactions

Febuxostat is contraindicated for use with certain medications, including azathioprine and mercaptopurine. Combining these drugs can lead to dangerously high levels of the other medications in the blood, increasing the risk of severe toxicity.

Gout Flares

An increase in gout flares is common when starting febuxostat because of the rapid change in uric acid levels. This does not mean the medication is not working, and other medications are often prescribed alongside febuxostat to help prevent these flares during the first few months of treatment.

Pregnancy

There are no adequate and well-controlled studies of febuxostat use in pregnant women. In animal research, no developmental abnormalities were observed even at doses much higher than the standard human dose. However, because animal studies are not always predictive of human response, febuxostat should only be used during pregnancy if a healthcare provider determines that the potential benefit justifies the potential risk to the fetus.

Breastfeeding

It is not known whether febuxostat is excreted in human breast milk. Research has shown that the drug is present in the milk of lactating rats. Because many drugs are passed through breast milk and have the potential for serious adverse reactions in nursing infants, caution is recommended. Individuals who are breastfeeding or planning to breastfeed should discuss the risks and benefits with their healthcare provider to determine the best course of action.

Consult Your Healthcare Provider

If you are pregnant, planning to become pregnant, or are currently breastfeeding, it is important to inform your doctor before starting or continuing febuxostat. They can help evaluate your specific medical needs against the potential risks to the infant or fetus.

Dosage Forms

Febuxostat is currently available in the following form for oral administration:

• Oral Tablet: This medication is taken by mouth, typically once daily, and can be taken with or without food.

FDA Approval and Indications

The U.S. Food and Drug Administration (FDA) approved febuxostat in 2009 for the chronic management of hyperuricemia (high levels of uric acid in the blood) in adults with gout. It is specifically indicated for patients who have already experienced gout attacks. It is not recommended for the treatment of high uric acid levels that do not cause symptoms.

Boxed Warning

In 2019, the FDA required the addition of a Boxed Warning—the agency's most serious type of warning—to the prescribing information for febuxostat. This action followed the review of a large clinical safety trial which found an increased risk of heart-related death and death from all causes in patients treated with febuxostat compared to those treated with allopurinol, another gout medication.

Usage Restrictions

Because of the increased risk of death, the FDA has restricted the use of febuxostat. It is now only indicated for use in patients who have had an inadequate response to a maximally escalated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable.

Safety Communications

The FDA advises healthcare professionals to monitor patients for cardiovascular signs and symptoms. Patients are encouraged to seek immediate medical care if they experience chest pain, shortness of breath, rapid or irregular heartbeat, sudden numbness or weakness on one side of the body, or slurred speech while taking this medication.

Generic vs. Brand Name

Febuxostat is available as a generic medication, which is typically much less expensive than the brand-name version, Uloric. Generic drugs are required to have the same active ingredients and strength as the brand-name product, offering a more affordable treatment option for most patients.

Insurance and Medicare Coverage

Most commercial insurance plans and Medicare Part D programs provide coverage for generic febuxostat. However, because it is often considered a second-line treatment after allopurinol, some insurance companies may require step therapy. This means you may be required to try a less expensive medication first before the insurance provider will approve coverage for febuxostat.

Factors Influencing Price

Several factors can affect the final price you pay at the pharmacy:

• Pharmacy Choice: Prices can vary between large retail chains, independent pharmacies, and mail-order services.
• Dosage and Quantity: The cost may differ based on whether you are prescribed the 40 mg or 80 mg strength and whether you purchase a 30-day or 90-day supply.
• Discount Programs: Patients without insurance or those with high copays may be able to use pharmacy discount cards or manufacturer assistance programs to reduce out-of-pocket costs.

Because febuxostat carries specific safety warnings regarding heart health, insurance companies may also have specific clinical criteria that must be met before they authorize the medication.